The Neat-HER virtual registry: Updated results on HER2+breast cancer patients receiving neratinib as extended adjuvant therapy.

被引：0
|
作者：
Vidal, Gregory A.
Tripathy, Debu
Hill, Nina
Lalla, Deepa
Hanson, Gillian
Drozd, Daniel R.
Xu, Feng
Rugo, Hope S.
机构：
[1] West Canc Ctr & Res Inst, Memphis, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Puma Biotechnol Inc, San Francisco, CA 94143 USA
[4] Puma Biotechnol Inc, Los Angeles, CA USA
[5] PicnicHealth, San Francisco, CA USA
[6] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e13565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13565
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The Neat-HER Virtual Registry: Results on HER2+breast cancer patients receiving neratinib as extended adjuvant therapy
    Rugo, Hope S.
    Vidal, Gregory A.
    Oestreicher, Nina
    Lalla, Deepa
    Hanson, Gillian
    Zhong, Yi
    Tripathy, Debu
    CANCER RESEARCH, 2021, 81 (04)
  • [2] The Neat-HER Virtual Registry: Results on HER2+ Breast Cancer Patients Receiving Neratinib as Extended Adjuvant Therapy
    Rugo, Hope S.
    Vidal, Gregory A.
    Oestreicher, Nina
    Lalla, Deepa
    Hanson, Gillian
    Zhong, Yi
    Tripathy, Debu
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 16 - 17
  • [3] The Neat-HER Virtual Registry: A novel registry following HER2+ESBC patients receiving neratinib in the extended adjuvant setting.
    Tripathy, Debu
    Vidal, Gregory A.
    Lalla, Deepa
    Bryce, Richard
    Hanson, Gillian
    Brammer, Melissa
    Xu, Feng
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Neratinib in extended adjuvant therapy for HER2-positive early breast cancer
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (04): : 201 - 205
  • [5] Association between treatment duration and overall survival in early-stage HER2+breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial
    Overkamp, Friedrich
    Moy, Beverly
    Coudert, Bruno
    Wong, Alvin
    Chan, Arlene
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 31 - 31
  • [6] Association between treatment duration and overall survival in early-stage HER2+breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
    Moy, Beverly
    Takahashi, Masato
    Ohtani, Shoichiro
    Chmielowska, Ewa
    Yamamoto, Naohito
    Coudert, Bruno P.
    Xu, Feng
    Wong, Alvin F.
    Chan, Arlene
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
    Caputo, Roberta
    Buono, Giuseppe
    Lauro, Vincenzo Di
    Cianniello, Daniela
    Arx, Claudia Von
    Pensabene, Matilde
    Pagliuca, Martina
    Pacilio, Carmen
    Rella, Francesca Di
    Verrazzo, Annarita
    Martinelli, Claudia
    Nuzzo, Francesco
    De Laurentiis, Michelino
    FUTURE ONCOLOGY, 2023, 19 (24) : 1695 - 1708
  • [8] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
    Michael Untch
    Miguel Martin
    Michelino De Laurentiis
    Joseph Gligorov
    Oncology and Therapy, 2021, 9 : 297 - 309
  • [9] How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
    Untch, Michael
    Martin, Miguel
    de Laurentiis, Michelino
    Gligorov, Joseph
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 297 - 309
  • [10] Adjuvant therapy for HER2+breast cancer: practice, perception, and toxicity
    Rocque, Gabrielle
    Onitilo, Adedayo
    Engel, Jessica
    Pettke, Erica
    Boshoven, Alice
    Kim, KyungMann
    Rishi, Shailly
    Waack, Bonnie
    Wisinski, Kari B.
    Tevaarwerk, Amye
    Burkard, Mark E.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 713 - 721
12345